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Introduction
Due to its low cost, its bedside applicability and its non-
invasiveness, cardiac ultrasound has developed into a 
widely used diagnostic tool in many heart diseases. The 
diagnostic possibilities increased even further with the 
introduction of microbubbles. In 1968, Gramiak and Shah 
were the first to report the use of microbubbles.1 In general, 
the microbubble currently consists of a high-molecular-
weight, gas-filled core to prevent it from dissolving in the 
pulmonary vasculature. This gas is encapsulated in a lipid 
or albumin shell, depending on the manufacturer.2
The composition of microbubbles makes them very 
good scatterers of ultrasound in contrast to erythrocytes, 
resulting in enhancement of the ultrasound image, thereby 
increasing diagnostic possibilities.3
Recently, attention has shifted to potential therapeutic 
applications of contrast ultrasound not only in the field of 
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cardiology, but also in cerebrovascular4 and peripheral vas-
cular disease.5 It was known that local application of ultra-
sound can cause bioeffects.6,7 The addition of microbubbles 
lowers the threshold for these effects to take place, thereby 
potentially enhancing these bioeffects. It has been demon-
strated in vitro and in vivo that contrast ultrasound has a 
potential therapeutic effect in acute ST elevation myocar-
dial infarction (STEMI).
Coronary thrombosis
STEMI is most often caused by the acute formation of a 
thrombus blocking an epicardial coronary artery, and current 
treatment strategies are focused on the prompt revascularisa-
tion of the occluded coronary artery. According to American 
College of Cardiology/American Heart Association (ACC/
AHA) and European Society of Cardiology (ESC) guide-
lines, the first choice of treatment is primary percutaneous 
coronary intervention (PCI).8,9 However, in rural areas, pri-
mary PCI is not available within 90 minutes of first patient 
contact. In those areas, thrombolysis is the next best therapy. 
Worldwide, thrombolysis remains the most used therapy in 
STEMI patients, despite its lower recanalisation rate and 
higher haemorrhagic complication rate compared to PCI. 
Hence, there is a continuing search for an easily applicable, 
non-invasive treatment strategy resulting in higher recanali-
sation rates with lower complication rates.
Pathophysiology
Low-frequency, high-intensity ultrasound. Hong et al. were 
one of the first to prove the potential for ultrasound-induced 
cavitation to dissolve thrombi in vitro.10 They used low-
frequency, high-intensity ultrasound with different-sized 
probes to treat blood clots, and observed that all clots were 
disrupted in less than 3 minutes. The size of the particles of 
the disrupted blood clot ranged from 2.5 to 80 µm. The 
addition of Streptokinase®, a thrombolytic agent, did not 
seem to have a measurable effect on the particle size distri-
bution. Another study performed by Rosenschein and col-
leagues confirmed these results in vitro.11 They also 
conducted an in vivo study in dogs, which led to a signifi-
cant decrease in thrombus obstruction, without an increase 
in wall injury of the treated vessel.12
After these successful in vitro and in vivo studies with 
high-intensity ultrasound, two small non-randomized stud-
ies presented good results regarding safety, feasibility and 
thrombus dissolution based on Thrombolysis in Myocardial 
Infarction (TIMI) flow.13,14 However, since it was an inva-
sive approach that did not significantly improve recanali-
sation rates compared to PCI, further development of 
high-intensity ultrasound to dissolve thrombi came to a halt.
Low-intensity, high-frequency ultrasound. A disadvantage of 
transcutaneous high-intensity, low-frequency ultrasound is 
the fact that it is not readily available in daily clinical practice. 
At lower intensities and long pulse durations, a number of 
studies have been conducted with these ultrasound settings to 
evaluate the effect on thrombi. It was demonstrated that low-
intensity ultrasound alone was unable to enhance clot dissolu-
tion. However, on top of a thrombolytic agent (e.g. tissue 
plasminogen activator [t-PA]), it was observed that throm-
bolysis was accelerated compared to treatment of thrombus 
with t-PA alone.15
Cavitation. Thus, both high- and low-intensity ultrasound 
seem to be able to enhance clot dissolution.16 Nevertheless, 
both approaches have an essentially different working 
mechanism. Where high-intensity ultrasound is capable of 
clot dissolution on its own under the influence of inertial 
cavitation, this effect does not occur using low-intensity 
ultrasound. Instead, it was thought that low-intensity 
ultrasound causes stable cavitation, thus creating local 
microstreaming. While lower-intensity ultrasound on its 
own may not be capable of enhancing clot dissolution, it is 
effective at increasing local concentrations of exogenously 
administered t-PA, thereby enhancing thrombolysis. This 
was nicely shown in an in vitro study performed by Sakha-
rov and colleagues.17 They demonstrated when ultrasound 
was applied without stirring that it accelerated lysis by about 
two-fold. However, in the presence of mild or strong stirring 
around the thrombus, ultrasound only slightly enhanced 
thrombolysis. The fact that ultrasound still enhanced throm-
bolysis in the presence of strong stirring was largely 
explained by the local temperature rise, which is another 
feature of the application of low-intensity ultrasound.18
Contrast ultrasound. Tachibana and Tachibana hypothe-
sised that the addition of microbubbles would lower the 
threshold for cavitation when using low-intensity ultra-
sound.19 They tested this by creating fresh thrombi using 
whole venous blood drawn from a healthy volunteer. 
These thrombi were divided in three groups, with each 
group receiving a different treatment strategy: either Uro-
kinase® alone, Urokinase® and ultrasound or Urokinase®, 
ultrasound and microbubbles. Low-intensity ultrasound 
was applied for 3 minutes at 170 kHz and 0.5 W/cm2 in an 
on–off sequence (2 seconds on and 4 seconds off). After 
treatment, the thrombi were incubated and weighed at dif-
ferent time periods. After 60 minutes, a significant differ-
ence was found between the three groups. Treatment with 
ultrasound alone resulted in an increase in thrombolysis, 
as expected. However, the addition of microbubbles on 
top of ultrasound and Urokinase® enhanced the thrombo-
lytic effect even further.19
In 2007, Prokop et al. carried out an experiment to test 
which form of cavitation results in ultrasound-accelerated, 
t-PA-mediated fibrinolysis.20 Although inertial cavitation was 
detected at the start of the experiment with contrast ultra-
sound on top of t-PA, this was not the dominant mechanism 
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for enhanced fibrinolysis. When the microbubbles were pre-
treated with ultrasound to prevent inertial cavitation, the 
reduction in clot weight was the same without pre-treatment, 
confirming that stable cavitation is the key mechanism 
for ultrasound-enhanced fibrinolysis after the addition of 
microbubbles.20
The different composure of microbubbles might also 
influence the results. However, this has never been fully 
explored. Therefore, clinical trials today are performed 
using commercially available microbubbles.
Effect of pulse duration. These results were confirmed in a 
study performed by Petit et al.21 Additionally, they also 
demonstrated that, in order for stable cavitation to enhance 
fibrinolysis, a longer pulse length is needed. A longer 
pulse duration results in a higher temporal average inten-
sity, which can sustain any induced microbubble cavita-
tional activity. These in vitro results were confirmed in an 
in vivo study performed by Xie et al.22 Using a diagnostic 
ultrasound system, they demonstrated in an atheroscle-
rotic pig model with STEMI that even a slightly longer 
pulse duration (20 µs) resulted in higher recanalisation 
rates (Figure 1). When using a diagnostic ultrasound sys-
tem, it was observed that thrombus age and the angle of 
the transducer also had influences on the thrombolytic 
effect of contrast ultrasound.7
All of these studies were performed with intermittent 
applications of ultrasound in order for microvascular 
replenishment to occur in between the high mechanical 
index (MI) impulses. The pulse durations were not pro-
longed further than 20 µs in order to prevent unwanted side 
effects, such as vascular wall damage and haemolysis, seen 
with longer pulse durations or continuous-wave ultra-
sound.12 There is another advantage of using image-guided, 
interrupted ultrasound, as it permits the visual assessment 
of the effect of treatment (Figure 2).
Despite these successful preliminary studies, the opti-
mal ultrasound settings remain a matter of debate. In addi-
tion, when applying it clinically in acute STEMI, 
attenuation plays an important role, making it difficult to 
establish the optimal settings when translating these 
results to human studies.23
Targeted contrast ultrasound. Another potential advantage 
of contrast ultrasound is the possibility of targeting micro-
bubbles to a site of interest, by conjugating the microbubble 
surface with agents that would adhere to upregulated recep-
tors. At first, it was thought that microbubbles passed freely 
through the microcirculation. However, it was discovered 
that this was not the case in inflamed or injured tissue. Acti-
vated neutrophils and monocytes cause microbubbles with 
an albumin or phosphatidyl serine-containing lipid shell to 
bind and become phagocytosed. In this circumstance, the 
microbubble remains acoustically active and thus creates 
an increased ultrasound signal locally.24
More specific targeting strategies can be utilised to 
enhance thrombus dissolution with ultrasound and micro-
bubbles (sonothrombolysis). By incorporating a single-
chain antibody specific for activated glycoprotein IIb/IIIa 
into the lipid shell of the microbubble, the interaction with 
activated platelets can be enhanced, thereby locally increas-
ing the concentration of microbubbles and thus increasing 
signal intensity.25 Positive results with targeted contrast 
ultrasound have already been demonstrated in an in vivo 
pig study by Xie et al.26 A recent study with both targeted 
ultrasound and targeted fibrinolytic agents in an in vivo 
mouse model demonstrated promising results not only with 
respect to increased fibrinolysis, but also with respect to 
lower bleeding risks.27,28
Clinical trials
The first sonothrombolysis trials in humans were performed 
with non-diagnostic ultrasound systems at low frequencies. 
Figure 1. Macrovascular effect of ultrasound and 
microbubbles, resulting in increased concentrations of t-PA due 
to microstreaming and thrombus disruption due to cavitation. 
(A) illustrates a total occlusion of a coronary artery due to 
thrombus formation. (B) illustrates improvement of flow under 
the influence of ultrasound and cavitating microbubbles.
t-PA: tissue plasminogen activator.
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Cohen and colleagues were the first to investigate the effect 
of ultrasound-enhanced thrombolysis in 25 patients with an 
acute STEMI.29 After patients were pre-treated with throm-
bolytics, low-frequency ultrasound was applied for 60 min-
utes, followed by a coronary angiogram. With 64% of the 
patients having TIMI III flow after treatment, results com-
pared favourably with historical data.
However, the PLUS trial, a large, multicentre, ran-
domised, clinical trial examining the effect of low-fre-
quency ultrasound added to fibrinolytic agents, was halted 
after an interim analysis in 360 patients demonstrated a lack 
of treatment efficacy, both in TIMI flow grade as in ST seg-
ment resolution.30 No microbubbles or image-guided ther-
apy were used in both trials.
Our group was the first to conduct a feasibility study using 
diagnostic ultrasound and commercially available microbub-
bles to the treatment protocol. Although it involved only 10 
patients, this first trial demonstrated that sonothrombolysis 
was safe and feasible.31 Subsequent to this, Mathias Jr et al. 
published the results of a large clinical trial using contrast 
ultrasound with different ultrasound settings in acute STEMI 
patients.32 Prior to PCI, there was a significantly higher epi-
cardial coronary recanalisation rate in the patient group 
receiving image-guided, high-mechanical index impulses. 
Interestingly, in contrast to in vitro and in vivo studies, even 
patients treated with a short pulse duration (3-4 µs) had a 
higher epicardial recanalisation rate. Microvascular flow also 
appeared improved, indicating that other factors, in addition 
to the sonothrombolytic effect, may be improving early and 
longer-term outcomes.32
Microvascular obstruction
The introduction of primary PCI improved revascularisa-
tion rates significantly for patients with STEMI. However, 
in up to 50% of patients, myocardial perfusion has remained 
poor in the area at risk.33 The causes of this persistent 
microvascular obstruction (MVO) can be categorised into 
four different pathogenetic components, which are distal 
embolisation, injury caused by ischemia, injury caused by 
reperfusion and individual predisposition. Contrast ultra-
sound may improve outcomes by affecting one or all of 
these components, and may potentially reduce the fre-
quency of MVO in STEMI.
Pathophysiology
During a study aiming for epicardial recanalisation using 
contrast ultrasound in combination with thrombolysis, Xie 
et al. encountered an improvement in microvascular flow 
despite an absence of epicardial coronary recanalisation.34 
It was therefore hypothesised that contrast ultrasound has a 
potential therapeutic effect on microvascular perfusion, 
reducing the effect of MVO. This was confirmed in a 
microvascular rat model by Leeman et al.35 In this study, 
the authors demonstrated that both intermittently applied 
higher mechanical index and longer pulse duration 
improved microvascular blood flow in a pure model of 
microvascular thrombotic obstruction. In a later study, 
using the same model, t-PA was added, resulting in an 
improvement of microvascular reperfusion.36 Recently, 
Belcik et al. confirmed these results in a hind limb ischemia 
mouse model using contrast ultrasound, and the authors 
observed that this improvement in microvascular flow 
lasted for more than 24 hours.37
Even though the exact mechanism underlying this 
improvement in microvascular flow might not be known, a 
fair amount of studies with contrast ultrasound have been 
conducted in order to explore the effect on cellular level 
and thereby its potential beneficial effect on MVO.
Figure 2. Change in replenishment kinetics during treatment of an acute ST elevation myocardial infarction, confirmed on coronary 
angiography (total occlusion of the left anterior descending artery (LAD), pointed out by the arrow).21 (Courtesy of Dr TR Porter, 
University of Nebraska Medical Center, Omaha, Nebraska, USA). MI: mechanical index.
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Nitric oxide. It is known that when the balance between nitric 
oxide (NO) synthesis and superoxide production falls in 
favour of superoxide production after reperfusion, this will 
result in vasoconstriction and exacerbation of the inflamma-
tory state.38 Increasing the amount of NO release might coun-
teract this imbalance after reperfusion. Therefore, it was 
hypothesised that vasodilation due to the release of NO was 
one of the main contributors to this improvement in local per-
fusion. This was subsequently demonstrated by pre-treating 
animals with L-Nω-nitroarginine methyl ester (L-NAME), a 
strong inhibitor of NO synthase. This time, tissue perfusion 
units (TPU) and pH did not improve under the influence of 
ultrasound.39 These results were confirmed in another in vivo 
study where the coronary arteries of nine dogs and five pigs 
were occluded, and local myocardial perfusion improved in 
both groups after treatment with low-frequency ultrasound.40
In a rat study using the same pure microvascular thrombo-
sis protocol used by Leeman et al.,35 intermittent high-
mechanical index impulses and 20-µs pulse duration 
ultrasound were applied through a tissue-mimicking phan-
tom in order to simulate transthoracic attenuation, and this 
proved effective at improving microvascular flow during a 
commercially available microbubble infusion.41 In this study, 
when the NO synthase inhibitor L-NAME was administered, 
there was a higher perivascular haemorrhage rate. Thus, NO 
production induced by diagnostic ultrasound high MI 
impulses may be preventing unwanted bioeffects.41
In an animal study by Xie and colleagues, microbubbles 
were added on top of ultrasound and t-PA.26,34 They also 
detected an increase in microvascular flow in the peri-infarct 
zone, despite the absence of epicardial coronary recanalisa-
tion. Since ultrasound-induced microbubble cavitation 
causes local shear stress on both thrombus and endothelial 
borders, it was postulated that local mechanical forces stim-
ulate endothelial cells to produce NO.42 This mechanism of 
stimulating the release of NO might be due to the production 
of intracellular hydrogen peroxide (H2O2). In a study per-
formed by Juffermans et al., the production of intracellular 
H2O2 was detected in vitro after treatment of the endothelial 
cell with contrast ultrasound.43 This intracellular H2O2 has 
been shown to stimulate the production of NO by the activa-
tion of endothelial NO synthase, counteracting the imbal-
ance between NO synthesis and superoxide production that 
occurs after reperfusion (Figure 3).44 The duration and 
intensity of cavitation induced by ultrasound, as well as the 
cellular environment in which cavitation occurs, may influ-
ence what bioeffect is observed. For example, if microbub-
bles are phagocytosed by neutrophil granulocytes, there 
may be amplification of superoxide generation, even prior 
to ultrasound-induced cavitation.45,46 However, once 
high-intensity ultrasound with a long pulse duration was 
applied, a decrease in superoxide generation was observed. 
Nevertheless, the application of high-intensity ultrasound 
caused an increase in apoptosis, membrane injury and com-
plete cell destruction. This effect was stronger using albu-
min microbubbles compared to lipid microbubbles.45 
Therefore, further investigation of the optimal ultrasound 
intensity setting in combination with microbubbles is 
Figure 3. Microvascular effect of ultrasound and microbubbles on an endothelial cell level, resulting in a decreased inflammatory 
response, leading to vasodilation through: (1) activation of shear stress resulting in an increase in intracellular H2O2, which results 
in the production of extracellular NO; (2) a decrease of superoxide; and (3) a decrease in rolling/adhered leukocytes. (A) The 
untreated situation without ultrasound; (B) treatment with ultrasound.
NO: nitric oxide; H2O2: hydrogen peroxide; O2–: superoxide.
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needed, in addition to exploring what effect that surround-
ing cellular environment has on outcome.
Inflammatory response. Another important mechanism 
resulting in reperfusion injury is the activation of the 
inflammatory response. Under the influence of changes in 
the local mechanical forces and the increased local release 
of reactive oxygen species after reperfusion, there is an 
increase in leukocyte adhesion. These activated leukocytes 
in turn enhance the inflammatory response, can form 
aggregates with platelets and release vasoconstrictors like 
superoxide.47 Decreasing the inflammatory response might 
have a positive effect on the microcirculation after isch-
emia/reperfusion, resulting in a lower prevalence of MVO 
(Figure 3). In several in vivo studies, it has been demon-
strated that application of ultrasound alone at the area 
where ischemia/reperfusion was created resulted in local 
vasodilation and a decrease in the number of rolling and 
adhered leukocytes. When microbubbles were added in this 
setting, ultrasound application further enhanced vasodila-
tion and decreased the number of leukocytes.48–50
Interestingly, in an in vivo mouse model, no clear disrup-
tion of leukocytes could be observed after application of 
ultrasound with a mechanical index of 0.9 to phagocytosed 
microbubbles.51
Clinical trials
The first-in-human, Phase II trial has been performed by 
Roos et al.52 In this study aiming at improving microvas-
cular reperfusion with a longer pulse duration (20 µs), 
ultrasound in combination with microbubbles was used to 
treat patients at up to a maximum of 15 minutes prior to 
PCI and 30 minutes post-PCI. Unfortunately, the study 
was discontinued after six patients, as the investigators 
encountered coronary spasm of the culprit vessel in 50% 
of the patients. These results were confirmed in a pig 
model when a blockage of the LAD was created by bal-
loon injury and thrombus injection and treated with long-
pulse duration ultrasound.52
Although contrast ultrasound has been shown to improve 
microvascular perfusion despite absent epicardial coronary 
recanalisation, the full mechanism of this effect still remains 
unclear. Furthermore, pulse duration seems to play an 
important role in enhancing microvascular perfusion. 
Nevertheless, it also results in local vasoconstriction. 
Further research is warranted in order to investigate the 
working mechanism, as well as the optimal settings.
Safety and feasibility
Concerns have also risen regarding possible adverse 
effects of the treatment of reperfusion injury using con-
trast ultrasound. It has been demonstrated that high-
intensity, focused ultrasound results in platelet activation, 
especially in the presence of inertial cavitation.53,54 When 
microbubbles were added, it was demonstrated that only 
at very high microbubble concentrations could platelets 
be activated, and when ultrasound was applied, there was 
a significant further increase in platelet activation. It 
must be emphasised that these results were obtained in 
platelet-rich plasma and with high concentrations of 
microbubbles. With normal concentrations of microbub-
bles added to samples of whole blood, no significant 
increase in platelet activation was observed, not even 
after ultrasound application.55
Furthermore, it was also shown that high-intensity ultra-
sound can perforate normal vessel walls.12 Nevertheless, 
this effect was only observed at very high intensities in an 
in vitro study using tissue from a necropsy. In vivo studies 
did not encounter this adverse effect.
Another safety issue encountered was coronary spasm 
during contrast ultrasound with longer pulse durations dur-
ing a Phase II trial, which was therefore halted at an early 
stage.52 The intensity and pulse duration seem to play 
important roles in both mechanical effects as well as 
adverse effects. Nevertheless, several in-human studies 
have been performed thus far, demonstrating safety and 
feasibility (Table 1).
Future directions
With the recent publication of the positive results by 
Mathias Jr et al.,32 the next step is to initiate a larger, multi-
centre, randomised, clinical trial aiming to improve both 
epicardial coronary recanalisation as well as MVO using 
contrast ultrasound in STEMI patients. Since the group 
treated with high-mechanical index impulses and shorter 
pulse durations demonstrated a higher epicardial recanali-
sation rate without signs of coronary spasm, it seems to be 
appropriate to use these settings in future studies. In addi-
tion to ST resolution on an electrocardiogram and epicar-
dial recanalisation on angiography, magnetic resonance 
imaging and myocardial contrast echocardiography might 
also be performed in order to examine the effects of these 
impulse on the subsequent frequency of MVO at specific 
time points following treatment.
Technical issues
When taking all of the different settings into consideration 
for reaching an optimal therapeutic effect and preventing 
serious side effects, it raises the question as to whether this 
new therapy is limited to centres with extensive experience. 
Since the largest improvement in epicardial thrombus dis-
solution can be obtained in the prehospital setting, care 
should be taken with future research that a protocol will be 
developed that can be performed in this prehospital setting 
by non-experienced users. The same goes for treatment of 
MVO using contrast ultrasound after primary PCI has been 
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performed. This also calls for the development of a device, 
such as an ultrasound vest, which could be transported in 
the prehospital setting and is easy to use.
Summary
We focused on the therapeutic application of contrast ultra-
sound in STEMI. A considerable amount of research has 
been performed to demonstrate that contrast ultrasound 
enhances thrombolysis. Although the exact working mech-
anism remains to be elucidated, it is known that destruction 
of microbubbles and local application of ultrasound induces 
several bioeffects, resulting in enhanced thrombolysis. 
Multiple animal infarct studies confirmed the therapeutic 
application of contrast ultrasound in STEMI, and the first 
human studies show promising results.
The aforementioned animal studies also demonstrated 
that despite an absence of epicardial coronary recanalisa-
tion, the peripheral perfusion of the area at risk did 
improve, indicating microvascular effects that are inde-
pendent of upstream vascular flow and obstruction. This 
may be mediated by cavitation-induced activation of 
purinergic pathways, leading to prolonged increases in NO 
production that have a positive influence on the imbalance 
between NO and superoxide production and subsequent 
inflammatory responses. There does appear to be an ultra-
sound dose–response curve in the setting of a microbubble 
infusion, in that inertial cavitation at a longer pulse dura-
tion may cause unwanted vasospasm in the presence of 
microbubbles. Pulse duration seems to be playing a major 
role in these side effects. Nevertheless, the local destruc-
tion of microbubbles under the influence of ultrasound 
might have a positive effect on MVO. Therefore, further 
research is warranted in order to explore the potential 
application of contrast ultrasound in patients suffering 
MVO after successful primary PCI.
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